2022
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
European heart journal. Cardiovascular pharmacotherapy
PubMed • Publisher's siteResearch at a glance
Top areas of exploration
- Platelet Aggregation Inhibitors , 13 publications
- Clopidogrel , 10 publications
- Ticagrelor , 9 publications
- Platelet Aggregation , 7 publications
Research activity
My publications
Filter publications
32 publications
2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
Thrombosis and haemostasis
PubMed • Publisher's site2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
European heart journal. Cardiovascular pharmacotherapy
PubMed • Publisher's site2021
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
JACC. Cardiovascular interventions
PubMed • Publisher's site2020
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thrombosis and haemostasis
PubMed • Publisher's site